Epigenetic modifications in obesity-associated diseases.

Yiqian Long, Chao Mao, Shuang Liu, Yongguang Tao, Desheng Xiao
Author Information
  1. Yiqian Long: Department of Pathology, Xiangya Hospital Central South University Changsha Hunan China.
  2. Chao Mao: Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, School of Basic Medicine Central South University Changsha Hunan China.
  3. Shuang Liu: Department of Pathology, Xiangya Hospital Central South University Changsha Hunan China.
  4. Yongguang Tao: Department of Pathology, Xiangya Hospital Central South University Changsha Hunan China. ORCID
  5. Desheng Xiao: Department of Pathology, Xiangya Hospital Central South University Changsha Hunan China.

Abstract

The global prevalence of obesity has reached epidemic levels, significantly elevating the susceptibility to various cardiometabolic conditions and certain types of cancer. In addition to causing metabolic abnormalities such as insulin resistance (IR), elevated blood glucose and lipids, and ectopic fat deposition, obesity can also damage pancreatic islet cells, endothelial cells, and cardiomyocytes through chronic inflammation, and even promote the development of a microenvironment conducive to cancer initiation. Improper dietary habits and lack of physical exercise are important behavioral factors that increase the risk of obesity, which can affect gene expression through epigenetic modifications. Epigenetic alterations can occur in early stage of obesity, some of which are reversible, while others persist over time and lead to obesity-related complications. Therefore, the dynamic adjustability of epigenetic modifications can be leveraged to reverse the development of obesity-associated diseases through behavioral interventions, drugs, and bariatric surgery. This review provides a comprehensive summary of the impact of epigenetic regulation on the initiation and development of obesity-associated cancers, type 2 diabetes, and cardiovascular diseases, establishing a theoretical basis for prevention, diagnosis, and treatment of these conditions.

Keywords

References

  1. Cancer. 2017 Sep 15;123(18):3617-3627 [PMID: 28543182]
  2. Nutr Diabetes. 2022 Dec 19;12(1):50 [PMID: 36535927]
  3. Nutrients. 2020 Jul 06;12(7): [PMID: 32640608]
  4. Cell. 2007 Feb 23;128(4):693-705 [PMID: 17320507]
  5. Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27412-27422 [PMID: 33087562]
  6. Br J Nutr. 2021 Jan 14;125(1):1-9 [PMID: 31685042]
  7. Nature. 2022 May;605(7908):160-165 [PMID: 35477756]
  8. Int J Mol Sci. 2019 Jun 14;20(12): [PMID: 31207998]
  9. J Diabetes Investig. 2021 Feb;12(2):165-175 [PMID: 32579760]
  10. Proteomics. 2024 Jun;24(11):e2300078 [PMID: 37525338]
  11. J Exp Med. 2021 May 3;218(5): [PMID: 33857282]
  12. Drugs. 2022 Nov;82(16):1621-1627 [PMID: 36380144]
  13. Antioxid Redox Signal. 2021 May 20;34(15):1165-1199 [PMID: 32808539]
  14. Bioessays. 2017 Jan;39(1):1-13 [PMID: 27859411]
  15. Med Sci Sports Exerc. 2022 Feb 1;54(2):353-368 [PMID: 35029593]
  16. Mol Med Rep. 2019 Mar;19(3):2180-2188 [PMID: 30747211]
  17. Cell Mol Life Sci. 2022 May 3;79(5):272 [PMID: 35503385]
  18. Endocr J. 2020 Apr 28;67(4):397-408 [PMID: 31875589]
  19. Clin Cancer Res. 2015 Nov 1;21(21):4767-73 [PMID: 26362997]
  20. Molecules. 2020 Jul 04;25(13): [PMID: 32635492]
  21. Cancer Epidemiol. 2016 Apr;41:8-15 [PMID: 26775081]
  22. Cytokine Growth Factor Rev. 2017 Dec;38:80-97 [PMID: 29158066]
  23. Genome Biol. 2018 Jan 23;19(1):7 [PMID: 29361968]
  24. Cell. 2020 Dec 23;183(7):1848-1866.e26 [PMID: 33301708]
  25. Front Endocrinol (Lausanne). 2023 Apr 21;14:1161521 [PMID: 37152942]
  26. Am J Respir Cell Mol Biol. 2021 Aug;65(2):214-221 [PMID: 33891828]
  27. Birth Defects Res. 2020 Oct;112(17):1308-1325 [PMID: 32476245]
  28. Obes Facts. 2022;15(4):540-549 [PMID: 35294947]
  29. Cell. 2018 May 17;173(5):1135-1149.e15 [PMID: 29754817]
  30. Diabetes. 2022 Oct 1;71(10):2136-2152 [PMID: 35822944]
  31. J Mol Endocrinol. 2014 Oct;53(2):191-200 [PMID: 24982244]
  32. BMC Cancer. 2019 Jan 18;19(1):86 [PMID: 30658617]
  33. Expert Opin Investig Drugs. 2007 Dec;16(12):1967-75 [PMID: 18042004]
  34. Mol Med Rep. 2022 Apr;25(4): [PMID: 35211764]
  35. Cell Rep. 2023 Aug 29;42(8):112928 [PMID: 37542720]
  36. Metabolism. 2023 Nov;148:155609 [PMID: 37277059]
  37. Atherosclerosis. 2020 Jan;292:119-126 [PMID: 31805451]
  38. Cell Metab. 2023 Jul 11;35(7):1147-1162.e7 [PMID: 37311455]
  39. J Med Chem. 2021 Jul 8;64(13):8827-8869 [PMID: 34161101]
  40. Biochem Biophys Res Commun. 2019 Feb 12;509(3):845-853 [PMID: 30638935]
  41. Leukemia. 2017 Jun;31(6):1434-1442 [PMID: 27885273]
  42. Noncoding RNA. 2023 Nov 02;9(6): [PMID: 37987363]
  43. Nat Rev Endocrinol. 2019 Mar;15(3):139-154 [PMID: 30459447]
  44. Endocr Relat Cancer. 2017 Jul;24(7):351-363 [PMID: 28442560]
  45. J Hematol Oncol. 2009 Jul 27;2:31 [PMID: 19635146]
  46. J Clin Invest. 1996 Sep 15;98(6):1277-82 [PMID: 8823291]
  47. Int J Gynecol Cancer. 2021 Jun;31(6):868-874 [PMID: 33911004]
  48. Int J Biochem Cell Biol. 2020 Feb;119:105667 [PMID: 31838177]
  49. Oncol Lett. 2021 Jul;22(1):508 [PMID: 33986869]
  50. iScience. 2021 Dec 25;25(1):103680 [PMID: 35036870]
  51. Nutrients. 2019 Jan 15;11(1): [PMID: 30650553]
  52. Indian J Clin Biochem. 2022 Jan;37(1):29-39 [PMID: 35125691]
  53. Nat Cell Biol. 2022 Jun;24(6):954-967 [PMID: 35637408]
  54. Front Endocrinol (Lausanne). 2020 Apr 23;11:245 [PMID: 32390948]
  55. J Exp Med. 2022 Jul 4;219(7): [PMID: 35652891]
  56. Front Physiol. 2021 Aug 19;12:728208 [PMID: 34489740]
  57. Signal Transduct Target Ther. 2021 Apr 2;6(1):135 [PMID: 33795651]
  58. J Exp Clin Cancer Res. 2020 Jan 2;39(1):4 [PMID: 31898515]
  59. MedComm (2020). 2024 Feb 24;5(2):e496 [PMID: 38405061]
  60. Prog Cardiovasc Dis. 2014 Jan-Feb;56(4):426-33 [PMID: 24438734]
  61. Theranostics. 2020 Mar 26;10(10):4705-4719 [PMID: 32292524]
  62. J Exp Med. 2021 May 3;218(5): [PMID: 33688917]
  63. Front Endocrinol (Lausanne). 2022 Aug 25;13:968268 [PMID: 36093112]
  64. Int J Biol Sci. 2021 Aug 27;17(14):3745-3759 [PMID: 35261562]
  65. Cell Death Dis. 2017 Jul 13;8(7):e2916 [PMID: 28703810]
  66. J Clin Invest. 2007 Jan;117(1):175-84 [PMID: 17200717]
  67. J Biomed Sci. 2014 Jun 14;21:59 [PMID: 24929539]
  68. Obes Facts. 2019;12(2):211-225 [PMID: 30999294]
  69. J Clin Oncol. 2016 Dec 10;34(35):4270-4276 [PMID: 27903155]
  70. J Agric Food Chem. 2023 Jun 21;71(24):9324-9336 [PMID: 37294881]
  71. J Nutr Biochem. 2022 Sep;107:109037 [PMID: 35533900]
  72. Cell Oncol (Dordr). 2022 Feb;45(1):85-101 [PMID: 35013999]
  73. Clin Cancer Res. 2016 May 1;22(9):2283-9 [PMID: 26712688]
  74. Cancers (Basel). 2018 Dec 27;11(1): [PMID: 30591653]
  75. Mol Cancer Res. 2020 Dec;18(12):1803-1814 [PMID: 32913111]
  76. Adipocyte. 2019 Dec;8(1):31-45 [PMID: 30474469]
  77. Cancer Res. 2010 Jul 1;70(13):5430-7 [PMID: 20516125]
  78. PLoS One. 2023 Mar 23;18(3):e0283608 [PMID: 36952563]
  79. Biomed Res Int. 2022 Jan 6;2022:9976909 [PMID: 35036445]
  80. Front Endocrinol (Lausanne). 2021 Jul 20;12:691658 [PMID: 34354670]
  81. Mol Metab. 2015 Mar 05;4(5):378-91 [PMID: 25973386]
  82. Front Genet. 2021 Oct 22;12:769690 [PMID: 34745232]
  83. Epigenetics. 2022 Dec;17(13):2082-2095 [PMID: 35938852]
  84. Int J Mol Sci. 2021 Jan 15;22(2): [PMID: 33467725]
  85. Clin Transl Med. 2022 Jun;12(6):e944 [PMID: 35735113]
  86. J Immunol. 2017 Oct 1;199(7):2191-2193 [PMID: 28923980]
  87. Trends Biotechnol. 2021 Jul;39(7):678-691 [PMID: 33972106]
  88. Expert Opin Pharmacother. 2020 Dec;21(18):2205-2213 [PMID: 32808831]
  89. Cell Rep. 2023 Jan 31;42(1):111948 [PMID: 36640325]
  90. Mol Cell. 2016 Apr 21;62(2):194-206 [PMID: 27105115]
  91. J Clin Endocrinol Metab. 2007 Jun;92(6):2240-7 [PMID: 17374712]
  92. Prog Lipid Res. 2006 Mar;45(2):120-59 [PMID: 16476485]
  93. Mol Oncol. 2021 Mar;15(3):790-800 [PMID: 32741068]
  94. Int J Environ Res Public Health. 2022 Jan 06;19(2): [PMID: 35055447]
  95. Nat Commun. 2021 Jun 28;12(1):3997 [PMID: 34183666]
  96. Nat Rev Mol Cell Biol. 2017 Jul;18(7):407-422 [PMID: 28512350]
  97. Diabetologia. 2020 Oct;63(10):2182-2193 [PMID: 32710190]
  98. Int J Mol Sci. 2019 May 22;20(10): [PMID: 31121868]
  99. J BUON. 2015 Jan-Feb;20(1):100-8 [PMID: 25778303]
  100. Obesity (Silver Spring). 2021 Jun;29(6):944-953 [PMID: 33616242]
  101. Diabetologia. 2023 Dec;66(12):2368-2386 [PMID: 37615690]
  102. Int J Mol Sci. 2021 Feb 17;22(4): [PMID: 33671464]
  103. J Nutr Biochem. 2022 Feb;100:108907 [PMID: 34801693]
  104. Acta Biochim Biophys Sin (Shanghai). 2018 Dec 1;50(12):1211-1218 [PMID: 30371726]
  105. J Hematol Oncol. 2017 Mar 15;10(1):69 [PMID: 28298231]
  106. Clin Epigenetics. 2021 Jan 23;13(1):16 [PMID: 33485366]
  107. Endocr Relat Cancer. 2017 Jul;24(7):365-378 [PMID: 28487351]
  108. Clin Epigenetics. 2022 Dec 18;14(1):176 [PMID: 36528638]
  109. Int J Mol Sci. 2021 Sep 30;22(19): [PMID: 34638914]
  110. Life (Basel). 2023 Sep 14;13(9): [PMID: 37763315]
  111. Cell Metab. 2021 Apr 6;33(4):781-790.e5 [PMID: 33450179]
  112. Sci Rep. 2022 Jun 16;12(1):10073 [PMID: 35710817]
  113. Diabetologia. 2023 Jun;66(6):1057-1070 [PMID: 36826505]
  114. Circ Res. 2021 Feb 19;128(4):474-491 [PMID: 33353368]
  115. Mol Ther. 2022 Jun 1;30(6):2274-2297 [PMID: 35292359]
  116. J Nutr Biochem. 2022 Dec;110:109119 [PMID: 35933021]
  117. Int J Obes (Lond). 2019 Jan;43(1):176-188 [PMID: 29717273]
  118. J Natl Cancer Inst. 2020 Mar 1;112(3):247-255 [PMID: 31161221]
  119. Circulation. 2021 May 25;143(21):e984-e1010 [PMID: 33882682]
  120. Annu Rev Biochem. 2009;78:273-304 [PMID: 19355820]
  121. Metabolism. 2021 Jun;119:154766 [PMID: 33766485]
  122. Oncotarget. 2018 Apr 20;9(30):21322-21336 [PMID: 29765542]
  123. Appl Physiol Nutr Metab. 2021 Aug;46(8):866-876 [PMID: 33493087]
  124. Front Oncol. 2021 May 21;11:631551 [PMID: 34094912]
  125. Ther Adv Hematol. 2015 Aug;6(4):202-8 [PMID: 26288714]
  126. Cell Commun Signal. 2023 Jan 23;21(1):18 [PMID: 36691020]
  127. Clin Epigenetics. 2018 Apr 17;10:54 [PMID: 29692867]
  128. Sci Rep. 2023 Mar 1;13(1):3467 [PMID: 36859458]
  129. Curr Hypertens Rep. 2014 Aug;16(8):463 [PMID: 24924994]
  130. Chembiochem. 2011 Jan 24;12(2):206-22 [PMID: 21243710]
  131. Gene. 2018 Mar 20;647:235-243 [PMID: 29317319]
  132. Cytokine Growth Factor Rev. 2021 Dec;62:23-41 [PMID: 34736827]
  133. Front Endocrinol (Lausanne). 2020 Oct 06;11:563816 [PMID: 33123088]
  134. Curr Obes Rep. 2018 Dec;7(4):260-275 [PMID: 30145771]
  135. Cancers (Basel). 2021 Jul 02;13(13): [PMID: 34283044]
  136. Am J Physiol Endocrinol Metab. 2014 Mar 1;306(5):E552-8 [PMID: 24398402]
  137. Hepatology. 2019 May;69(5):1931-1945 [PMID: 30584660]
  138. Curr Pharm Des. 2021;27(35):3729-3740 [PMID: 33845722]
  139. Cell Prolif. 2021 Dec;54(12):e13140 [PMID: 34647385]
  140. Cancer. 2017 Nov 1;123(21):4130-4138 [PMID: 28700821]
  141. Cell. 2007 Feb 23;128(4):683-92 [PMID: 17320506]
  142. Clin Epigenetics. 2023 Sep 7;15(1):144 [PMID: 37679776]
  143. J Clin Invest. 2015 Oct 1;125(10):3819-30 [PMID: 26368306]
  144. Nature. 2019 Jul;571(7766):489-499 [PMID: 31341302]
  145. Biomed Res Int. 2020 Nov 24;2020:8838676 [PMID: 33299884]
  146. Am J Physiol Endocrinol Metab. 2018 Aug 1;315(2):E150-E162 [PMID: 29634312]
  147. Blood. 2017 Aug 10;130(6):722-731 [PMID: 28588020]
  148. Annu Rev Biochem. 2020 Jun 20;89:135-158 [PMID: 31815535]
  149. PLoS One. 2015 Sep 24;10(9):e0138980 [PMID: 26401660]
  150. IUBMB Life. 2019 Dec;71(12):1952-1961 [PMID: 31408278]
  151. Commun Biol. 2023 Jan 27;6(1):105 [PMID: 36707678]
  152. Br J Pharmacol. 2020 Mar;177(6):1331-1350 [PMID: 31691272]
  153. Science. 2023 Feb 10;379(6632):eaaw3835 [PMID: 36758093]
  154. Int Immunopharmacol. 2020 Sep;86:106741 [PMID: 32650294]
  155. Hepatology. 2020 Aug;72(2):454-469 [PMID: 31782176]
  156. Aging (Albany NY). 2022 Mar 24;14(6):2902-2919 [PMID: 35332108]
  157. Cardiol Res Pract. 2021 Jun 02;2021:8840698 [PMID: 34123418]
  158. Cell Rep. 2021 Aug 3;36(5):109487 [PMID: 34348140]
  159. Int J Obes (Lond). 2022 Jun;46(6):1122-1127 [PMID: 35165382]
  160. Expert Opin Pharmacother. 2007 Jan;8(1):65-73 [PMID: 17163808]
  161. Cell Rep. 2018 Jan 16;22(3):624-637 [PMID: 29346762]
  162. Mol Ther Nucleic Acids. 2019 Mar 1;14:192-203 [PMID: 30623853]
  163. Cell Metab. 2019 May 7;29(5):1028-1044 [PMID: 30982733]
  164. Nat Commun. 2022 Jan 10;13(1):69 [PMID: 35013251]
  165. Nat Immunol. 2021 May;22(5):550-559 [PMID: 33707781]
  166. Int J Mol Sci. 2016 Jul 29;17(8): [PMID: 27483249]
  167. Dis Markers. 2022 Jul 18;2022:8902916 [PMID: 35899178]
  168. Epigenetics. 2017 Jan 2;12(1):55-69 [PMID: 27858497]
  169. Nat Commun. 2023 May 15;14(1):2543 [PMID: 37188670]
  170. J Physiol Biochem. 2019 Aug;75(3):391-401 [PMID: 31321740]
  171. Nat Metab. 2019 Jul;1(7):688-703 [PMID: 32694641]
  172. Sci Rep. 2019 Mar 25;9(1):5100 [PMID: 30911103]
  173. Sci Rep. 2017 Jan 03;7:39918 [PMID: 28045102]
  174. Front Cell Dev Biol. 2022 Mar 08;10:818082 [PMID: 35350384]
  175. J Clin Invest. 2021 Aug 2;131(15): [PMID: 34338228]
  176. Gene. 2023 Mar 1;855:147125 [PMID: 36549426]
  177. Front Cell Dev Biol. 2022 Apr 04;10:804247 [PMID: 35445015]
  178. Cell Death Discov. 2022 May 20;8(1):268 [PMID: 35595755]
  179. Eur J Prev Cardiol. 2024 Jan 25;31(2):191-202 [PMID: 37793095]
  180. Front Cell Dev Biol. 2023 Feb 16;11:1101844 [PMID: 36875756]
  181. Gene. 2024 Feb 15;895:147988 [PMID: 37977322]
  182. BMC Cancer. 2019 Jan 21;19(1):93 [PMID: 30665376]
  183. Cell. 2011 Aug 5;146(3):353-8 [PMID: 21802130]
  184. Epigenetics. 2021 Apr;16(4):458-467 [PMID: 32749195]
  185. Diabetol Metab Syndr. 2021 Jan 22;13(1):10 [PMID: 33482868]
  186. Diabetes Care. 2022 Jul 7;45(7):1621-1630 [PMID: 35607770]
  187. J Natl Cancer Inst. 2023 Apr 11;115(4):456-467 [PMID: 36647199]
  188. Isr Med Assoc J. 2017 Oct;19(10):620-624 [PMID: 29103239]
  189. FEBS J. 2021 Jun;288(12):3663-3682 [PMID: 32798313]
  190. Cancer Cell. 2017 Nov 13;32(5):574-589.e6 [PMID: 29136504]
  191. Mol Cancer Res. 2017 Sep;15(9):1163-1172 [PMID: 28512251]
  192. J Clin Oncol. 2014 Nov 1;32(31):3568-74 [PMID: 25273035]
  193. J Biol Chem. 2007 May 4;282(18):13316-25 [PMID: 17344214]
  194. Genes Dis. 2022 Jun 03;10(6):2393-2413 [PMID: 37554181]
  195. J Gene Med. 2019 Oct;21(10):e3120 [PMID: 31415715]
  196. Curr Nutr Rep. 2018 Sep;7(3):97-106 [PMID: 30128963]
  197. Life Sci. 2018 Aug 15;207:127-137 [PMID: 29705354]
  198. Int J Mol Sci. 2023 Feb 03;24(3): [PMID: 36769291]
  199. Mol Metab. 2023 Sep;75:101774 [PMID: 37429525]
  200. Mol Metab. 2020 Mar;33:102-121 [PMID: 31399389]
  201. Front Endocrinol (Lausanne). 2023 Apr 05;14:1167546 [PMID: 37091852]
  202. Drugs. 2020 Apr;80(5):513-521 [PMID: 32166598]
  203. Mol Nutr Food Res. 2020 Aug;64(16):e2000326 [PMID: 32618118]
  204. J Hematol Oncol. 2015 Oct 29;8:122 [PMID: 26514126]
  205. Biomolecules. 2021 Jun 20;11(6): [PMID: 34202969]
  206. J Cell Physiol. 2019 Aug;234(10):17959-17974 [PMID: 30847933]
  207. Genome Med. 2022 Jun 23;14(1):67 [PMID: 35739588]
  208. J Bioenerg Biomembr. 2021 Jun;53(3):333-342 [PMID: 33826088]
  209. Sci Rep. 2023 Nov 9;13(1):19496 [PMID: 37945677]
  210. Genes Dev. 2001 Sep 15;15(18):2343-60 [PMID: 11562345]
  211. Sci Transl Med. 2018 Apr 18;10(437): [PMID: 29669855]
  212. Acta Pharmacol Sin. 2022 May;43(5):1285-1298 [PMID: 34417576]
  213. Anticancer Agents Med Chem. 2017;17(8):1093-1101 [PMID: 28002999]
  214. Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):671-682 [PMID: 29844585]
  215. Expert Rev Anticancer Ther. 2014 Apr;14(4):463-85 [PMID: 24580550]
  216. CA Cancer J Clin. 2019 Mar;69(2):88-112 [PMID: 30548482]
  217. Acta Pharm Sin B. 2023 Jun;13(6):2403-2424 [PMID: 37425065]
  218. Biomed Res Int. 2021 Jun 29;2021:5516078 [PMID: 34307654]
  219. Cancer Res. 2019 Jan 1;79(1):196-208 [PMID: 30389702]
  220. Eur J Clin Invest. 2023 Mar;53(3):e13912 [PMID: 36424669]
  221. Expert Opin Drug Discov. 2017 Aug;12(8):859-873 [PMID: 28641053]
  222. Nat Med. 2019 Jan;25(1):141-151 [PMID: 30420753]
  223. Acta Diabetol. 2022 Jul;59(7):885-899 [PMID: 35347427]
  224. Cell Death Differ. 2021 Jun;28(6):1880-1899 [PMID: 33462408]
  225. Mol Cell Biochem. 2022 Apr;477(4):1095-1106 [PMID: 35064875]
  226. Lancet Diabetes Endocrinol. 2020 Aug;8(8):703-718 [PMID: 32707118]
  227. Gut. 2023 Oct;72(10):1848-1865 [PMID: 36948576]
  228. Cell. 2009 Feb 20;136(4):629-41 [PMID: 19239885]
  229. CA Cancer J Clin. 2023 Jan;73(1):17-48 [PMID: 36633525]
  230. Am J Physiol Heart Circ Physiol. 2021 Mar 1;320(3):H999-H1016 [PMID: 33416454]
  231. BMC Cardiovasc Disord. 2023 Sep 11;23(1):450 [PMID: 37697228]
  232. J Steroid Biochem Mol Biol. 2021 May;209:105843 [PMID: 33588025]
  233. Sci Rep. 2017 Sep 6;7(1):10714 [PMID: 28878369]
  234. Nat Commun. 2019 Sep 25;10(1):4358 [PMID: 31554818]
  235. Biomedicines. 2022 Jul 29;10(8): [PMID: 36009379]
  236. Adv Sci (Weinh). 2021 May 02;8(11):2004507 [PMID: 34141522]
  237. J Cancer Res Clin Oncol. 2020 Oct;146(10):2461-2477 [PMID: 32685988]
  238. Nutrients. 2023 Feb 04;15(4): [PMID: 36839169]
  239. Mol Cell Biol. 2017 Aug 11;37(17): [PMID: 28630279]
  240. Int J Mol Sci. 2021 Sep 28;22(19): [PMID: 34638838]
  241. Front Endocrinol (Lausanne). 2023 Oct 23;14:1286838 [PMID: 37941908]
  242. J Pers Med. 2020 Oct 14;10(4): [PMID: 33066497]
  243. Environ Res. 2023 Dec 15;239(Pt 1):117266 [PMID: 37775001]
  244. Int J Mol Sci. 2021 Nov 28;22(23): [PMID: 34884678]
  245. Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Dec;1866(12):159045 [PMID: 34450266]
  246. Int J Mol Sci. 2022 Apr 09;23(8): [PMID: 35456983]
  247. Curr Drug Targets. 2022;23(8):836-853 [PMID: 35078394]
  248. Nat Rev Genet. 2019 Nov;20(11):675-691 [PMID: 31395983]
  249. J Am Coll Cardiol. 2022 Sep 13;80(11):1091-1106 [PMID: 36075680]
  250. J Clin Lab Anal. 2022 Mar;36(3):e24263 [PMID: 35098570]
  251. Nat Rev Genet. 2012 May 29;13(7):484-92 [PMID: 22641018]
  252. Nat Commun. 2022 May 26;13(1):2958 [PMID: 35618718]
  253. Nat Rev Mol Cell Biol. 2012 Jan 23;13(2):115-26 [PMID: 22266761]
  254. Br J Nutr. 2019 Sep 14;122(5):499-508 [PMID: 30157990]
  255. Prostate Cancer Prostatic Dis. 2017 Dec;20(4):418-423 [PMID: 28653675]
  256. Life Sci. 2023 Jan 1;312:121246 [PMID: 36455651]
  257. Cell Death Dis. 2019 Mar 11;10(3):243 [PMID: 30858356]
  258. Obes Rev. 2021 Oct;22(10):e13319 [PMID: 34278703]
  259. Epigenet Insights. 2021 Jan 28;14:2516865720988567 [PMID: 33598635]
  260. Nat Rev Genet. 2017 Sep;18(9):517-534 [PMID: 28555658]
  261. J Pers Med. 2022 Apr 20;12(5): [PMID: 35629083]
  262. Hepatology. 2021 May;73(5):1797-1815 [PMID: 33058300]
  263. J Leukoc Biol. 2019 Feb;105(2):317-327 [PMID: 30303554]
  264. Atherosclerosis. 2017 Aug;263:325-333 [PMID: 28577936]
  265. J Clin Med. 2019 Jul 17;8(7): [PMID: 31319558]
  266. Adipocyte. 2021 Dec;10(1):108-118 [PMID: 33570456]
  267. J Clin Lab Anal. 2022 Aug;36(8):e24583 [PMID: 35778952]
  268. Front Cardiovasc Med. 2021 Nov 19;8:768026 [PMID: 34869683]
  269. JAMA. 2022 Jun 28;327(24):2423-2433 [PMID: 35657620]
  270. NPJ Breast Cancer. 2021 Aug 13;7(1):105 [PMID: 34389732]
  271. Adipocyte. 2021 Dec;10(1):493-504 [PMID: 34699309]
  272. Int J Obes (Lond). 2022 Feb;46(2):333-341 [PMID: 34716428]
  273. Commun Biol. 2022 Jun 7;5(1):553 [PMID: 35672444]
  274. Diabetes Metab J. 2021 Nov;45(6):799-812 [PMID: 34847640]
  275. Adv Ther. 2019 Jan;36(1):44-58 [PMID: 30465123]
  276. Front Oncol. 2020 Jul 02;10:1089 [PMID: 32714872]
  277. J Clin Invest. 2003 Dec;112(12):1796-808 [PMID: 14679176]
  278. Food Funct. 2021 Oct 19;12(20):9620-9631 [PMID: 34549226]
  279. J Nutr Biochem. 2022 Oct;108:109092 [PMID: 35718098]
  280. Front Endocrinol (Lausanne). 2023 Feb 10;14:1106529 [PMID: 36843614]
  281. Sci Rep. 2019 Dec 30;9(1):20271 [PMID: 31889127]
  282. Cell Metab. 2016 May 10;23(5):770-84 [PMID: 27166942]
  283. Diabetol Metab Syndr. 2022 Aug 18;14(1):117 [PMID: 35982478]
  284. Front Physiol. 2023 Mar 30;14:1143966 [PMID: 37064893]
  285. Clin Sci (Lond). 2017 Jul 5;131(15):1841-1857 [PMID: 28533215]
  286. Cancer Cell Int. 2020 Jun 24;20:266 [PMID: 32595415]
  287. Curr Obes Rep. 2017 Mar;6(1):18-27 [PMID: 28205155]
  288. Lancet. 2014 Mar 22;383(9922):1068-83 [PMID: 24315620]
  289. Crit Rev Food Sci Nutr. 2022;62(14):3855-3872 [PMID: 33427492]
  290. Front Oncol. 2020 Feb 18;10:61 [PMID: 32133283]
  291. Trends Endocrinol Metab. 2018 Aug;29(8):529-531 [PMID: 29884327]
  292. J Physiol. 2023 Sep;601(17):3961-3974 [PMID: 37470310]
  293. Exp Mol Pathol. 2020 Jun;114:104405 [PMID: 32084395]
  294. Cancers (Basel). 2020 May 14;12(5): [PMID: 32422865]
  295. J Biol Chem. 2021 Nov;297(5):101250 [PMID: 34592314]

Word Cloud

Created with Highcharts 10.0.0obesitydiseasescancancerdevelopmentepigeneticmodificationsobesity-associatedconditionscellsinitiationbehavioralEpigenetictype2cardiovascularpreventionglobalprevalencereachedepidemiclevelssignificantlyelevatingsusceptibilityvariouscardiometaboliccertaintypesadditioncausingmetabolicabnormalitiesinsulinresistanceIRelevatedbloodglucoselipidsectopicfatdepositionalsodamagepancreaticisletendothelialcardiomyocyteschronicinflammationevenpromotemicroenvironmentconduciveImproperdietaryhabitslackphysicalexerciseimportantfactorsincreaseriskaffectgeneexpressionalterationsoccurearlystagereversibleotherspersisttimeleadobesity-relatedcomplicationsThereforedynamicadjustabilityleveragedreverseinterventionsdrugsbariatricsurgeryreviewprovidescomprehensivesummaryimpactregulationcancersdiabetesestablishingtheoreticalbasisdiagnosistreatmentepigeneticstherapy

Similar Articles

Cited By (4)